医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

2019年01月21日 AM09:05
このエントリーをはてなブックマークに追加


 

TOKYO

At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group. (Hereinafter, the “Group” refers to two companies, SanBio Co., Ltd., and SanBio, Inc.)

1. Details of the Decision

As part of its mission to introduce new therapeutic drugs for the central nervous system, the Group is moving forward with the development of programs for chronic motor deficit from traumatic brain injury (TBI) and chronic motor deficit from ischemic stroke, centering on the United States and Japan. Regarding the program for treatment of chronic motor deficit from TBI, positive results were announced on November 1, 2018, with respect to a Phase 2 clinical trial, namely that “Patients administered SB623 demonstrated a statistically significant improvement in their motor function compared to the control group, confirming that the study has met its primary endpoint.” Regarding the program targeting chronic motor deficit from ischemic stroke, the Company expects to announce results of a Phase 2b clinical trial in the first half of the fiscal year ending January 31, 2020 (from February 1, 2019 to July 31, 2019).

Given the positive results of the program targeting chronic motor deficit from TBI mentioned above, the Group has reevaluated the scope of indications for SB623. Consequently, the Company has decided to initiate a program for treatment of chronic motor deficit from cerebral hemorrhage, which is similar to TBI, as a new indication for SB623. The Company is considering Japan and the United States as development regions for this program.

Ischemic stroke is caused by the blockage of blood vessels, whereas cerebral hemorrhage results from ruptured blood vessels. Both can result in hemiplegia, sensory impairment, or memory impairment. Currently, no definitive therapy exists.

As of today, the Company expects to commence clinical trials for this program from Phase 2 or Phase 3. However, the development details and timing are not yet decided. The Company will provide these as soon as they become available.

2. Outlook

This decision does not affect the Company’s consolidated operating performance for the fiscal year ending January 31, 2019.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190120005025/en/

CONTACT

SanBio Co., Ltd.
Yoshihiro Kakutani, Corporate Officer of
Management Administration
(TEL. +81-3-6264-3481)

同じカテゴリーの記事 

  • Fast Fitness Japan Obtains Master Franchisee Rights for Anytime Fitness in Germany
  • ATLATL Scientific and Miltenyi Biotec: A Five-Year Partnership Driving Biotech Innovation in Singapore and Beyond
  • 世界経済フォーラム(WEF)特別会合リヤドが閉幕平和と繁栄への明確で不可逆的な道をグローバルな最優先課題とすることを呼びかける
  • 世界经济论坛特别会议闭幕,全球领导人呼吁:探寻通往和平与繁荣的清晰、不可逆转路径应为全球首要任务
  • Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial